The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research Report: Human FBXO16 (UniProt Q8IX29) — Functional Annotation

0) Target verification (mandatory)

The literature gathered here consistently studies FBXO16 (F-box only protein 16) as an F-box domain–containing substrate-receptor component of CRL1/SCF (CUL1–SKP1–RBX1) ubiquitin ligase complexes, matching the target identity and domain logic in UniProt (F-box domain(s) plus additional C-terminal substrate-recognition region). No evidence reviewed corresponded to a different gene with a confusingly similar symbol. (ji2021fbxo16mediatedhnrnplubiquitination pages 1-2, ji2021fbxo16mediatedhnrnplubiquitination pages 6-8, ji2021fbxo16mediatedhnrnplubiquitination pages 4-6)

1) Key concepts & definitions (current understanding)

1.1 F-box proteins and SCF/CRL1 E3 ligases

F-box proteins are generally understood to function as substrate-recognition receptors in SCF/CRL1 E3 ubiquitin ligase complexes, where the F-box motif mediates association with SKP1, and the cullin scaffold (CUL1) with RBX1 recruits an E2 enzyme to catalyze ubiquitin transfer to substrates. FBXO16 behaves consistently with this architecture: its F-box domain is required for assembling functional ubiquitin-ligase activity, whereas a C-terminal region mediates substrate binding/recognition. (ji2021fbxo16mediatedhnrnplubiquitination pages 6-8, ji2021fbxo16mediatedhnrnplubiquitination pages 4-6, khan2019attenuationoftumor pages 4-6, sugimotoishige2025fbxo16mediatesdegradation pages 8-9)

1.2 What “E3 ligase substrate receptor” means for FBXO16 function

For FBXO16, the “primary function” is not to catalyze a chemical reaction like an enzyme active site; rather, it confers substrate specificity on a ubiquitin ligase complex by binding selected proteins and positioning them for polyubiquitination and usually proteasomal degradation (often via K48-linked polyubiquitin). (khan2019attenuationoftumor pages 4-6, zhang2024mir937amplificationpotentiates pages 7-10, ji2021fbxo16mediatedhnrnplubiquitination pages 8-9)

2) FBXO16 molecular function: substrates, mechanisms, and domains

2.1 Validated substrates (experimentally supported)

Across primary mechanistic studies, FBXO16 has been experimentally validated to target multiple proteins for ubiquitin-dependent degradation:

1. β-catenin (CTNNB1): FBXO16 physically interacts with β-catenin and promotes K48-linked polyubiquitination and proteasome-mediated degradation of the nuclear pool of β-catenin, suppressing Wnt/TCF transcriptional output. (khan2019attenuationoftumor pages 1-2, khan2019attenuationoftumor pages 4-6)
2. hnRNPL: FBXO16 assembles a canonical SCF complex via its F-box domain and targets hnRNPL for ubiquitination and degradation; substrate recognition maps to the FBXO16 C-terminus, binding the RRM3 domain of hnRNPL. (ji2021fbxo16mediatedhnrnplubiquitination pages 1-2, ji2021fbxo16mediatedhnrnplubiquitination pages 6-8, ji2021fbxo16mediatedhnrnplubiquitination pages 8-9)
3. ULK1: In ovarian cancer models, FBXO16 binds ULK1 and promotes K48-linked polyubiquitination and reduced ULK1 protein abundance, thereby suppressing autophagy outputs. (zhang2024mir937amplificationpotentiates pages 7-10)
4. NF-κB p65/RELA (functional substrate in immune context): Fbxo16 was identified as a substrate-recognition component in a PDLIM2-containing CRL1 complex that promotes p65 polyubiquitination and degradation in nuclear compartments, suppressing NF-κB activation. (sugimotoishige2025fbxo16mediatesdegradation pages 6-7, sugimotoishige2025fbxo16mediatesdegradation pages 8-9)

2.2 Domain logic (F-box vs. substrate-binding region)

Two consistent structure–function principles emerge:

• The F-box domain is required for complex formation and ubiquitination function (e.g., ΔF-box mutants fail to promote ubiquitination of targets or to form productive complexes). (ji2021fbxo16mediatedhnrnplubiquitination pages 6-8, sugimotoishige2025fbxo16mediatesdegradation pages 8-9)
• The C-terminal region is repeatedly implicated in substrate recognition:
• For β-catenin, a C-terminal deletion abolishes binding to β-catenin, while F-box or N-terminal deletions can retain interaction, indicating substrate binding is C-terminally mediated. (khan2019attenuationoftumor pages 4-6, khan2019attenuationoftumor pages 2-3)
• For hnRNPL, FBXO16 binds hnRNPL via its C-terminal region to hnRNPL’s RRM3 domain. (ji2021fbxo16mediatedhnrnplubiquitination pages 1-2, ji2021fbxo16mediatedhnrnplubiquitination pages 8-9)
• For ULK1, the study explicitly tests an FBXO16 ΔCTD construct in functional assays, implying CTD importance for FBXO16 inhibitory function. (zhang2024mir937amplificationpotentiates pages 7-10)

2.3 Mechanistic visualization (figure evidence)

Khan et al. provide direct figure-level evidence supporting: (i) FBXO16–β-catenin interaction, (ii) increased total and K48-linked ubiquitination of nuclear β-catenin with FBXO16 expression, and (iii) domain mapping showing the C-terminus is essential for β-catenin interaction. (khan2019attenuationoftumor media a83ab1b6)

3) Cellular localization & where FBXO16 acts

FBXO16 functional evidence strongly emphasizes nuclear contexts:

• In glioblastoma models, FBXO16 targets the nuclear fraction of β-catenin for K48-linked polyubiquitination and degradation. (khan2019attenuationoftumor pages 1-2, khan2019attenuationoftumor pages 4-6)
• In ovarian cancer, FBXO16 is reported as mainly nuclear and targets nuclear hnRNPL, consistent with its substrate being a predominantly nuclear RNA-binding protein. (ji2021fbxo16mediatedhnrnplubiquitination pages 4-6, ji2021fbxo16mediatedhnrnplubiquitination pages 1-2)
• In immune signaling studies, Fbxo16 promotes p65 degradation in nuclear/intranuclear compartments and shifts p65 to an insoluble nuclear fraction prior to proteasomal degradation. (sugimotoishige2025fbxo16mediatesdegradation pages 8-9)

Taken together, FBXO16 appears to be a nuclear-relevant CRL1 substrate receptor with substrate-dependent localization (and some evidence for both cytoplasmic and nuclear presence in the NF-κB study’s discussion referencing HPA). (sugimotoishige2025fbxo16mediatesdegradation pages 7-8)

4) Pathways and biological processes regulated by FBXO16

4.1 Wnt/β-catenin signaling (tumor suppression via β-catenin turnover)

FBXO16 suppresses Wnt signaling by promoting nuclear β-catenin degradation. In glioblastoma models, this is linked to reduced expression of canonical β-catenin/TCF outputs such as c-Myc and Cyclin D1, reduced TOPFlash reporter activity, and reduced malignant phenotypes. (khan2019attenuationoftumor pages 4-6, khan2019attenuationoftumor pages 1-2)

4.2 RNA-binding protein regulation and oncogenic pathway control (hnRNPL axis)

In ovarian cancer models, FBXO16-mediated hnRNPL degradation is associated with suppression of malignant phenotypes and reduction of multiple oncogenic signaling outputs. In FBXO16 KO conditions, hnRNPL knockdown was sufficient to reverse activation of MAPK, RAS, and Wnt signaling described in that study. (ji2021fbxo16mediatedhnrnplubiquitination pages 8-9)

4.3 Autophagy initiation (ULK1 axis)

A 2024 study identifies ULK1 as a degradation substrate of FBXO16 and links FBXO16 to autophagy suppression: FBXO16 overexpression reduces ULK1 and shifts autophagy markers (e.g., lower LC3II/I ratio, increased p62), while FBXO16 knockdown increases ULK1 protein. (zhang2024mir937amplificationpotentiates pages 7-10)

4.4 NF-κB inflammatory signaling (p65/RELA axis)

In dendritic cell contexts, Fbxo16 functions as a substrate receptor for p65 in a PDLIM2-containing CRL1 complex; Fbxo16 promotes p65 degradation and thereby limits NF-κB transactivation and pro-inflammatory cytokine expression (e.g., IL-6). (sugimotoishige2025fbxo16mediatesdegradation pages 6-7, sugimotoishige2025fbxo16mediatesdegradation pages 8-9)

5) Recent developments (prioritizing 2023–2024)

5.1 2024: MIR937 amplification → FBXO16 downregulation → ULK1 stabilization → increased autophagy

Zhang et al. (published Oct 2024 in Cell Death & Disease) propose and experimentally support a regulatory axis where MIR937 amplification increases miR-937-5p, which targets the 3′ UTR of FBXO16, reducing FBXO16 levels and thereby restricting FBXO16’s degradative effect on ULK1, promoting autophagy and proliferative capacity in high-grade serous ovarian cancer models. (zhang2024mir937amplificationpotentiates pages 7-10)

5.2 2023: disease-association and systems evidence (database aggregation)

Open Targets aggregates genetic/literature evidence linking FBXO16 to neoplasm-related terms and specific cancers (e.g., ovarian cancer, glioblastoma multiforme) and also reports associations for amyotrophic lateral sclerosis (ALS) in its evidence set. While these are not mechanistic proofs, they are useful for prioritizing disease contexts for follow-up experimentation. (OpenTargets Search: -FBXO16)

6) Current applications and real-world implementations

6.1 Biomarker and mechanistic target candidate in oncology

Primary mechanistic studies support FBXO16 as a tumor-suppressive regulator through degradation of oncogenic effectors (β-catenin, hnRNPL, ULK1-mediated autophagy), suggesting potential translational applications:

• Biomarker concept: low FBXO16 expression can be interpreted as permissive for elevated Wnt signaling (via β-catenin) or increased autophagy (via ULK1), depending on tumor type and context. (khan2019attenuationoftumor pages 1-2, zhang2024mir937amplificationpotentiates pages 7-10)
• Therapeutic hypothesis: strategies that restore FBXO16 function or mimic its substrate-degradation effects might suppress tumor growth programs mediated by β-catenin, hnRNPL, or ULK1. These are still preclinical hypotheses grounded in cell and xenograft models rather than clinical trials. (khan2019attenuationoftumor pages 4-6, ji2021fbxo16mediatedhnrnplubiquitination pages 8-9, zhang2024mir937amplificationpotentiates pages 7-10)

6.2 Targeting upstream regulators (noncoding RNA axes)

The 2024 MIR937/miR-937-5p → FBXO16 → ULK1 axis provides a concrete example of a potentially druggable regulatory layer: blocking miR-937-5p or restoring FBXO16 could reduce ULK1-mediated autophagy that supports tumor cell fitness. (zhang2024mir937amplificationpotentiates pages 7-10)

7) Expert interpretation and analysis (evidence-weighted)

7.1 Most confident functional statement

The strongest, repeatedly supported functional annotation is:

FBXO16 is a CRL1/SCF substrate-recognition protein that drives K48-linked polyubiquitination and proteasomal degradation of select substrates, with prominent nuclear activity.

This is supported by multiple primary mechanistic datasets across different substrates and contexts (β-catenin, hnRNPL, ULK1; nuclear p65 in immune context). (khan2019attenuationoftumor pages 4-6, ji2021fbxo16mediatedhnrnplubiquitination pages 8-9, zhang2024mir937amplificationpotentiates pages 7-10, sugimotoishige2025fbxo16mediatesdegradation pages 8-9)

7.2 Substrate selectivity and context dependence

FBXO16 substrates appear context-dependent (tumor type, cell state, and possibly binding partners like PDLIM2). For example, ULK1 is prominent in one ovarian cancer mechanism, while hnRNPL is emphasized in another; the ULK1-focused study notes hnRNPL is not altered in that specific context, implying separable substrate modules. (zhang2024mir937amplificationpotentiates pages 7-10)

7.3 C-terminal substrate-recognition as a unifying mechanistic theme

Independent substrate-mapping experiments converge on the FBXO16 C-terminus as a key substrate-binding interface (β-catenin, hnRNPL; likely ULK1). This suggests that perturbations in the C-terminal region (mutation, truncation, binding competition) could broadly disable FBXO16 substrate recognition even if SCF assembly remains intact. (khan2019attenuationoftumor pages 4-6, ji2021fbxo16mediatedhnrnplubiquitination pages 8-9)

8) Statistics and quantitative data from recent/primary studies

• Ovarian cancer clinical specimens (hnRNPL axis): In 68 ovarian cancer specimens, FBXO16 expression was negatively correlated with hnRNPL (χ² = 14.81, P < 0.001). (ji2021fbxo16mediatedhnrnplubiquitination pages 8-9)
• In vivo tumor growth (hnRNPL recognition domain): In SKOV3 xenografts (injection 1×10^7 cells; n = 5 mice), expression of hnRNPL lacking the FBXO16-recognition domain (ΔRRM3) increased tumor growth (P < 0.001), consistent with impaired FBXO16-mediated hnRNPL degradation promoting tumor growth. (ji2021fbxo16mediatedhnrnplubiquitination pages 8-9)
• β-catenin nuclear puncta: FBXO16 overexpression produced an approximately 4-fold reduction in nuclear RFP-β-catenin speckles in glioblastoma models, alongside reduced Wnt reporter output and downstream targets. (khan2019attenuationoftumor pages 4-6)
• Migration phenotype: FBXO16 overexpression reduced migration by ~30% (P ≤ 0.008) in the glioblastoma study excerpt. (khan2019attenuationoftumor pages 4-6)
• Disease association evidence counts (Open Targets): Open Targets lists FBXO16 associations for several diseases with evidence_size = 5 in its returned summary for diseases including glioblastoma multiforme, neoplasm, cervical carcinoma, ALS, and ovarian cancer. (OpenTargets Search: -FBXO16)

9) Evidence map summary table

The following table consolidates substrates, mechanisms, domains, localization, contexts, and key quantitative points.

Table: This table compiles experimentally supported evidence for human FBXO16 (UniProt Q8IX29), emphasizing validated substrates, SCF/CRL1 complex partners, domain requirements, compartment, biological context, and quantitative findings. It is useful as a compact functional-annotation map grounded in primary literature and citeable context IDs.

10) Limitations and open questions

1. UniProt accession reporting: The primary papers reviewed typically refer to FBXO16 by gene/protein name rather than explicitly stating UniProt Q8IX29; identity matching is therefore based on symbol/function/domain congruence rather than explicit accession mention. (ji2021fbxo16mediatedhnrnplubiquitination pages 1-2, khan2019attenuationoftumor pages 4-6)
2. Incomplete substrate landscape: While β-catenin, hnRNPL, ULK1, and p65 have evidence, the full substrate repertoire and recognition motifs remain incompletely defined. Context-dependent substrate selection is likely. (zhang2024mir937amplificationpotentiates pages 7-10)
3. Clinical translation: Evidence is largely mechanistic and preclinical (cell and xenograft models); no FBXO16-directed therapies or clinical trials were identified in the gathered evidence.

Key primary sources (with publication dates and URLs)

• Khan M, Muzumdar D, Shiras A. Attenuation of tumor suppressive function of FBXO16 ubiquitin ligase activates Wnt signaling in glioblastoma. Neoplasia. Jan 2019. https://doi.org/10.1016/j.neo.2018.11.005 (khan2019attenuationoftumor pages 4-6, khan2019attenuationoftumor media a83ab1b6)
• Ji M et al. FBXO16-mediated hnRNPL ubiquitination and degradation plays a tumor suppressor role in ovarian cancer. Cell Death & Disease. Jul 2021. https://doi.org/10.1038/s41419-021-04040-9 (ji2021fbxo16mediatedhnrnplubiquitination pages 1-2, ji2021fbxo16mediatedhnrnplubiquitination pages 8-9)

• Zhang Z et al. MIR937 amplification potentiates ovarian cancer progression by attenuating FBXO16 inhibition on ULK1-mediated autophagy. Cell Death & Disease. Oct 2024. https://doi.org/10.1038/s41419-024-07120-8 (zhang2024mir937amplificationpotentiates pages 7-10)

• Open Targets Platform (disease–target association aggregation for FBXO16). Accessed via tool output. https://platform.opentargets.org/ (OpenTargets Search: -FBXO16)

References

1. (ji2021fbxo16mediatedhnrnplubiquitination pages 1-2): Mei Ji, Zhao Zhao, Yue Li, Penglin Xu, Jia Shi, Zhe Li, Kaige Wang, Xiaotian Huang, Jing Ji, Wei Liu, and Bin Liu. Fbxo16-mediated hnrnpl ubiquitination and degradation plays a tumor suppressor role in ovarian cancer. Cell Death & Disease, Jul 2021. URL: https://doi.org/10.1038/s41419-021-04040-9, doi:10.1038/s41419-021-04040-9. This article has 34 citations and is from a peer-reviewed journal.

2. (ji2021fbxo16mediatedhnrnplubiquitination pages 6-8): Mei Ji, Zhao Zhao, Yue Li, Penglin Xu, Jia Shi, Zhe Li, Kaige Wang, Xiaotian Huang, Jing Ji, Wei Liu, and Bin Liu. Fbxo16-mediated hnrnpl ubiquitination and degradation plays a tumor suppressor role in ovarian cancer. Cell Death & Disease, Jul 2021. URL: https://doi.org/10.1038/s41419-021-04040-9, doi:10.1038/s41419-021-04040-9. This article has 34 citations and is from a peer-reviewed journal.

3. (ji2021fbxo16mediatedhnrnplubiquitination pages 4-6): Mei Ji, Zhao Zhao, Yue Li, Penglin Xu, Jia Shi, Zhe Li, Kaige Wang, Xiaotian Huang, Jing Ji, Wei Liu, and Bin Liu. Fbxo16-mediated hnrnpl ubiquitination and degradation plays a tumor suppressor role in ovarian cancer. Cell Death & Disease, Jul 2021. URL: https://doi.org/10.1038/s41419-021-04040-9, doi:10.1038/s41419-021-04040-9. This article has 34 citations and is from a peer-reviewed journal.

4. (khan2019attenuationoftumor pages 4-6): Mohsina Khan, Dattatraya Muzumdar, and Anjali Shiras. Attenuation of tumor suppressive function of fbxo16 ubiquitin ligase activates wnt signaling in glioblastoma. Jan 2019. URL: https://doi.org/10.1016/j.neo.2018.11.005, doi:10.1016/j.neo.2018.11.005. This article has 35 citations and is from a domain leading peer-reviewed journal.

5. (sugimotoishige2025fbxo16mediatesdegradation pages 8-9): Akiko Sugimoto-Ishige, Aya Jodo, and Takashi Tanaka. Fbxo16 mediates degradation of nf-κb p65 subunit and inhibits inflammatory response in dendritic cells. Frontiers in Immunology, Jun 2025. URL: https://doi.org/10.3389/fimmu.2025.1524110, doi:10.3389/fimmu.2025.1524110. This article has 3 citations and is from a peer-reviewed journal.

6. (zhang2024mir937amplificationpotentiates pages 7-10): Zhen Zhang, Xinkui Liu, Chu Chu, Yingjie Zhang, Wei Li, Xiaoyan Yu, Qiaoqiao Han, Haoyu Sun, Yunhong Zhang, Xiaoxiao Zhu, Liang Chen, Ran Wei, Nannan Fan, Miaomiao Zhou, and Xia Li. Mir937 amplification potentiates ovarian cancer progression by attenuating fbxo16 inhibition on ulk1-mediated autophagy. Cell Death & Disease, Oct 2024. URL: https://doi.org/10.1038/s41419-024-07120-8, doi:10.1038/s41419-024-07120-8. This article has 5 citations and is from a peer-reviewed journal.

7. (ji2021fbxo16mediatedhnrnplubiquitination pages 8-9): Mei Ji, Zhao Zhao, Yue Li, Penglin Xu, Jia Shi, Zhe Li, Kaige Wang, Xiaotian Huang, Jing Ji, Wei Liu, and Bin Liu. Fbxo16-mediated hnrnpl ubiquitination and degradation plays a tumor suppressor role in ovarian cancer. Cell Death & Disease, Jul 2021. URL: https://doi.org/10.1038/s41419-021-04040-9, doi:10.1038/s41419-021-04040-9. This article has 34 citations and is from a peer-reviewed journal.

8. (khan2019attenuationoftumor pages 1-2): Mohsina Khan, Dattatraya Muzumdar, and Anjali Shiras. Attenuation of tumor suppressive function of fbxo16 ubiquitin ligase activates wnt signaling in glioblastoma. Jan 2019. URL: https://doi.org/10.1016/j.neo.2018.11.005, doi:10.1016/j.neo.2018.11.005. This article has 35 citations and is from a domain leading peer-reviewed journal.

9. (sugimotoishige2025fbxo16mediatesdegradation pages 6-7): Akiko Sugimoto-Ishige, Aya Jodo, and Takashi Tanaka. Fbxo16 mediates degradation of nf-κb p65 subunit and inhibits inflammatory response in dendritic cells. Frontiers in Immunology, Jun 2025. URL: https://doi.org/10.3389/fimmu.2025.1524110, doi:10.3389/fimmu.2025.1524110. This article has 3 citations and is from a peer-reviewed journal.

10. (khan2019attenuationoftumor pages 2-3): Mohsina Khan, Dattatraya Muzumdar, and Anjali Shiras. Attenuation of tumor suppressive function of fbxo16 ubiquitin ligase activates wnt signaling in glioblastoma. Jan 2019. URL: https://doi.org/10.1016/j.neo.2018.11.005, doi:10.1016/j.neo.2018.11.005. This article has 35 citations and is from a domain leading peer-reviewed journal.

11. (khan2019attenuationoftumor media a83ab1b6): Mohsina Khan, Dattatraya Muzumdar, and Anjali Shiras. Attenuation of tumor suppressive function of fbxo16 ubiquitin ligase activates wnt signaling in glioblastoma. Jan 2019. URL: https://doi.org/10.1016/j.neo.2018.11.005, doi:10.1016/j.neo.2018.11.005. This article has 35 citations and is from a domain leading peer-reviewed journal.

12. (sugimotoishige2025fbxo16mediatesdegradation pages 7-8): Akiko Sugimoto-Ishige, Aya Jodo, and Takashi Tanaka. Fbxo16 mediates degradation of nf-κb p65 subunit and inhibits inflammatory response in dendritic cells. Frontiers in Immunology, Jun 2025. URL: https://doi.org/10.3389/fimmu.2025.1524110, doi:10.3389/fimmu.2025.1524110. This article has 3 citations and is from a peer-reviewed journal.

13. (OpenTargets Search: -FBXO16): Open Targets Query (-FBXO16, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

14. (sugimotoishige2025fbxo16mediatesdegradation pages 12-13): Akiko Sugimoto-Ishige, Aya Jodo, and Takashi Tanaka. Fbxo16 mediates degradation of nf-κb p65 subunit and inhibits inflammatory response in dendritic cells. Frontiers in Immunology, Jun 2025. URL: https://doi.org/10.3389/fimmu.2025.1524110, doi:10.3389/fimmu.2025.1524110. This article has 3 citations and is from a peer-reviewed journal.

15. (sugimotoishige2025fbxo16mediatesdegradation pages 5-6): Akiko Sugimoto-Ishige, Aya Jodo, and Takashi Tanaka. Fbxo16 mediates degradation of nf-κb p65 subunit and inhibits inflammatory response in dendritic cells. Frontiers in Immunology, Jun 2025. URL: https://doi.org/10.3389/fimmu.2025.1524110, doi:10.3389/fimmu.2025.1524110. This article has 3 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00
  

Citations

1. khan2019attenuationoftumor pages 4-6
2. khan2019attenuationoftumor pages 1-2
3. khan2019attenuationoftumor pages 2-3
4. https://doi.org/10.1016/j.neo.2018.11.005
5. https://doi.org/10.1038/s41419-021-04040-9
6. https://doi.org/10.1038/s41419-024-07120-8
7. https://doi.org/10.3389/fimmu.2025.1524110
8. https://platform.opentargets.org/
9. https://doi.org/10.1038/s41419-021-04040-9,
10. https://doi.org/10.1016/j.neo.2018.11.005,
11. https://doi.org/10.3389/fimmu.2025.1524110,
12. https://doi.org/10.1038/s41419-024-07120-8,